278 related articles for article (PubMed ID: 31187704)
21. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).
Rodriguez JB; Falcone BN; Szajnman SH
Expert Opin Ther Pat; 2016 Sep; 26(9):993-1015. PubMed ID: 27376456
[TBL] [Abstract][Full Text] [Related]
22. Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.
Sayé M; Gauna L; Valera-Vera E; Reigada C; Miranda MR; Pereira CA
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007481. PubMed ID: 31961864
[TBL] [Abstract][Full Text] [Related]
23. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
24. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
25. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
26. The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies.
Talevi A; Carrillo C; Comini M
Curr Med Chem; 2019; 26(36):6614-6635. PubMed ID: 30259812
[TBL] [Abstract][Full Text] [Related]
27. Primary evidence of the mechanisms of action of HIV aspartyl peptidase inhibitors on Trypanosoma cruzi trypomastigote forms.
Sangenito LS; Menna-Barreto RFS; Oliveira AC; d'Avila-Levy CM; Branquinha MH; Santos ALS
Int J Antimicrob Agents; 2018 Aug; 52(2):185-194. PubMed ID: 29635008
[TBL] [Abstract][Full Text] [Related]
28. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.
Maya JD; Cassels BK; Iturriaga-Vásquez P; Ferreira J; Faúndez M; Galanti N; Ferreira A; Morello A
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):601-20. PubMed ID: 16626984
[TBL] [Abstract][Full Text] [Related]
29. Repurposing Strategy of Atorvastatin against Trypanosoma cruzi:
Araujo-Lima CF; Peres RB; Silva PB; Batista MM; Aiub CAF; Felzenszwalb I; Soeiro MNC
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987140
[TBL] [Abstract][Full Text] [Related]
30. New Approaches for the Treatment of Chagas Disease.
Pandey RP; Nascimento MS; Moore CE; Raj VS; Kalil J; Cunha-Neto E
Curr Drug Targets; 2021; 22(7):835-841. PubMed ID: 33238855
[TBL] [Abstract][Full Text] [Related]
31. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
32. Drug repurposing for Chagas disease: In vitro assessment of nimesulide against Trypanosoma cruzi and insights on its mechanisms of action.
Trindade JDS; Freire-de-Lima CG; Côrte-Real S; Decote-Ricardo D; Freire de Lima ME
PLoS One; 2021; 16(10):e0258292. PubMed ID: 34679091
[TBL] [Abstract][Full Text] [Related]
33. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
34. Chagas Disease Chemotherapy: What Do We Know So Far?
Zuma AA; de Souza W
Curr Pharm Des; 2021; 27(38):3963-3995. PubMed ID: 33593251
[TBL] [Abstract][Full Text] [Related]
35. Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.
Juárez-Saldivar A; Schroeder M; Salentin S; Haupt VJ; Saavedra E; Vázquez C; Reyes-Espinosa F; Herrera-Mayorga V; Villalobos-Rocha JC; García-Pérez CA; Campillo NE; Rivera G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560043
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease.
Martín-Escolano R; Aguilera-Venegas B; Marín C; Martín-Montes Á; Martín-Escolano J; Medina-Carmona E; Arán VJ; Sánchez-Moreno M
ChemMedChem; 2018 Oct; 13(19):2104-2118. PubMed ID: 30098232
[TBL] [Abstract][Full Text] [Related]
37. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
38. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections.
Buckner FS
Adv Exp Med Biol; 2008; 625():61-80. PubMed ID: 18365659
[TBL] [Abstract][Full Text] [Related]
39. Developments on treatment of Chagas disease - from discovery to current times.
Custodio Leite TO
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
[TBL] [Abstract][Full Text] [Related]
40. Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.
Santos LO; Garcia-Gomes AS; Catanho M; Sodre CL; Santos AL; Branquinha MH; d'Avila-Levy CM
Curr Med Chem; 2013; 20(25):3116-33. PubMed ID: 23298141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
